12,560 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Symmetry Investments LP

Symmetry Investments LP purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,560 shares of the company’s stock, valued at approximately $11,372,000. Eli Lilly and Company makes up 1.3% of Symmetry Investments LP’s investment portfolio, making the stock its 18th biggest position.

Several other institutional investors also recently bought and sold shares of the business. Legacy Financial Advisors Inc. grew its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 2,948 shares of the company’s stock valued at $2,669,000 after acquiring an additional 44 shares during the period. Westwood Holdings Group Inc. lifted its holdings in Eli Lilly and Company by 1.9% during the second quarter. Westwood Holdings Group Inc. now owns 3,912 shares of the company’s stock valued at $3,542,000 after purchasing an additional 73 shares in the last quarter. Tcwp LLC lifted its holdings in Eli Lilly and Company by 2.3% during the second quarter. Tcwp LLC now owns 524 shares of the company’s stock valued at $474,000 after purchasing an additional 12 shares in the last quarter. Bulltick Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $224,000. Finally, Nkcfo LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $1,584,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the sale, the insider now directly owns 97,556,910 shares of the company’s stock, valued at approximately $88,033,404,445.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 442,229 shares of company stock valued at $410,002,456 over the last 90 days. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Berenberg Bank lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Truist Financial reissued a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Up 0.7 %

LLY stock opened at $921.72 on Friday. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The firm has a market cap of $876.01 billion, a PE ratio of 135.75, a PEG ratio of 2.79 and a beta of 0.42. The firm’s 50 day moving average price is $895.06 and its 200-day moving average price is $837.89. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were given a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.